Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Comparison with companies in other sectors?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has a share price of 3.88B. You can analyze Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) competitors across different market sectors through stock heatmaps.

What are SFOSF's NET and operating margins?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) operating margin is around 0.11, and net profit margin is approximately 0.07 as of the latest reports.

In what way does SFOSF's earnings per share (EPS) trend reflect its financial momentum?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) EPS is 0.15 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is 13.03, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. like P/E which is 12.76, P/B which is 0.78, and PEG which is 0.31. Compare them with sector averages to evaluate if the stock is priced fairly.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SFOSF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$1.96

$0.005(0.26%)

Fundamental Analysis of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.15

P/E Ratio

13.03

ROE

0.06%

Net Margin

0.07%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.58B

Shares OutstandingTotal number of shares issued

$3.88B

Book Value/ShareNet worth per share

$22.85

Revenue/ShareAnnual revenue per share

$15.12

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.15

Net MarginNet income as percentage of revenue

7.27%

Operating MarginOperating income as percentage of revenue

10.82%

ROEReturn on shareholders' equity

6.18%

ROAReturn on total assets

2.48%

ROCEReturn on capital employed

5.28%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.16

Cash/ShareCash and equivalents per share

$6.03

FCF YieldFree cash flow as percentage of market cap

0.81%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.32

Dividend YieldAnnual dividend as percentage of stock price

2.28%

Financial Ratios Analysis data is not available for SFOSFFinancial Ratios Analysis details for SFOSF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SFOSFSector Benchmarking details for SFOSF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

For Shanghai Fosun Pharmaceutical (Group) Co., Ltd., essential financial indicators include EPS 0.15, PE 13.03, and ROE 0.06. These key ratios reveal insights into Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Shanghai Fosun Pharmaceutical (Group) Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Metrics like Net Margin 7.27% and ROA 2.48% shed light on how well Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Shanghai Fosun Pharmaceutical (Group) Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Using ratios such as P/B Ratio 0.78 and PEG Ratio 0.31, investors can assess whether Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.67 and Cash Flow $0.16, provide a snapshot of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Investing in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Shanghai Fosun Pharmaceutical (Group) Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;